Comparative Pharmacology
Head-to-head clinical analysis: ANOQUAN versus XYLOCAINE 5 W GLUCOSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANOQUAN versus XYLOCAINE 5 W GLUCOSE 7 5.
ANOQUAN vs XYLOCAINE 5% W/ GLUCOSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
100 mg orally twice daily
Adult: 5-25 mL (250-1250 mg lidocaine) of 5% lidocaine with glucose 7.5% solution, administered by caudal or lumbar epidural injection, single dose. Max total dose: 1250 mg.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
1.5-2 hours (terminal); prolonged in heart failure, hepatic disease, or elderly; neonates 3-6 hours due to immature hepatic function.
Renal excretion accounts for approximately 70% of the dose (50% as unchanged drug, 20% as inactive metabolites); biliary/fecal excretion accounts for 30%.
Hepatic metabolism (90% N-dealkylation by CYP1A2/CYP3A4 to monoethylglycinexylidide and glycinexylidide); renal excretion of metabolites and parent drug (<10% unchanged); <1% biliary/fecal.
Category C
Category C
Local Anesthetic
Local Anesthetic